Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.
Program in Cellular and Molecular Medicine at Boston Children's Hospital, Boston, MA, 02115, USA.
Nat Biomed Eng. 2017 Nov;1(11):878-888. doi: 10.1038/s41551-017-0145-2. Epub 2017 Oct 9.
Gene disruption by clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) is highly efficient and relies on the error-prone non-homologous end-joining pathway. Conversely, precise gene editing requires homology-directed repair (HDR), which occurs at a lower frequency than non-homologous end-joining in mammalian cells. Here, by testing whether manipulation of DNA repair factors improves HDR efficacy, we show that transient ectopic co-expression of RAD52 and a dominant-negative form of tumour protein p53-binding protein 1 (dn53BP1) synergize to enable efficient HDR using a single-stranded oligonucleotide DNA donor template at multiple loci in human cells, including patient-derived induced pluripotent stem cells. Co-expression of RAD52 and dn53BP1 improves multiplexed HDR-mediated editing, whereas expression of RAD52 alone enhances HDR with Cas9 nickase. Our data show that the frequency of non-homologous end-joining-mediated double-strand break repair in the presence of these two factors is not suppressed and suggest that dn53BP1 competitively antagonizes 53BP1 to augment HDR in combination with RAD52. Importantly, co-expression of RAD52 and dn53BP1 does not alter Cas9 off-target activity. These findings support the use of RAD52 and dn53BP1 co-expression to overcome bottlenecks that limit HDR in precision genome editing.
通过成簇规律间隔短回文重复序列 (CRISPR)-CRISPR 相关蛋白 9 (Cas9) 进行基因敲除效率很高,并且依赖易错的非同源末端连接途径。相反,精确的基因编辑需要同源定向修复 (HDR),而在哺乳动物细胞中,HDR 的发生频率低于非同源末端连接。在这里,通过测试 DNA 修复因子的操纵是否能提高 HDR 的效率,我们表明,RAD52 和肿瘤蛋白 p53 结合蛋白 1 的显性失活形式 (dn53BP1) 的瞬时异位共表达协同作用,以在多个基因座中使用单链寡核苷酸 DNA 供体模板在人类细胞中,包括源自患者的诱导多能干细胞,实现高效的 HDR。RAD52 和 dn53BP1 的共表达可改善多重 HDR 介导的编辑,而单独表达 RAD52 可增强 Cas9 切口酶的 HDR。我们的数据表明,在这两种因子存在的情况下,非同源末端连接介导的双链断裂修复的频率没有受到抑制,并表明 dn53BP1 通过与 RAD52 竞争拮抗 53BP1 来增强 HDR。重要的是,RAD52 和 dn53BP1 的共表达不会改变 Cas9 的脱靶活性。这些发现支持使用 RAD52 和 dn53BP1 的共表达来克服限制精确基因组编辑中 HDR 的瓶颈。